Inocras and Massive Bio have entered a partnership to improve personalized cancer treatment and care.
The collaboration involves employing Inocras's whole-genome sequencing (WGS) and bioinformatics expertise with Massive Bio's AI technology for clinical trial matching, which will permit cancer patients to be informed of prospective clinical trials that align with their genetic profile without the need for additional tests. Massive Bio is expected to enhance the scope of trial enrollment by reducing screen failures using its predictive analytics.
The alliance aims to increase the benefits of precision medicine for cancer patients and deliver tailored cancer care based on individual genetic profiles.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.